AMICUS THERAPEUTICS, INC. — Director's Dealing 2023

Dec 28, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-12-26

Reporting Person: Rosenberg Ellen (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-26	Common Stock	M	30000	$5.16	Acquired	372285	Direct
2023-12-26	Common Stock	S	30000	$14.0028	Disposed	342285	Direct
2023-12-27	Common Stock	M	5000	$5.16	Acquired	347285	Direct
2023-12-27	Common Stock	S	5000	$14.0654	Disposed	342285	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-26	Stock Options (right to buy)	$5.16	M	30000	Disposed	2026-02-08	Common Stock (30000)	Direct
2023-12-27	Stock Options (right to buy)	$5.16	M	5000	Disposed	2026-02-08	Common Stock (5000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	15000	Indirect

Footnotes

F1: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.00 to $14.02 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.00 to $14.15 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of the options were fully vested and exercisable as of the transaction date.